Glox Therapeutics secures £4.3m to develop precision antimicrobials 14-Nov-2023 By Isabel Cameron Glox Therapeutics, a company developing precision antibiotic therapies based on naturally occurring bacteriocins, has raised £4.3m in seed funding to develop targeted therapeutics against antibiotic-resistant Gram-negative bacteria.